(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.
Jemperli, whose generic name is dostarlimab, plus chemotherapy is the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in the overall population, GSK said, citing data from its Ruby phase III trial.
The study found a 31% reduction in the risk of death and more than 16-month improvement in median overall survival, GSK said. The test was on adult patients with primary advanced or recurrent endometrial cancer, which occurs in the uterus and is sometimes called uterine cancer.
"The results we've seen to date comprise the growing body of evidence supporting the role of dostarlimab as the backbone of our immuno-oncology development programme," said Hesham Abdullah, global head of Oncology R&D at GSK.
"Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options."
Shares in the Brentford, Middlesex-based pharmaceutical company were flat at 1,650.40 pence early Monday in London.
By Tom Waite, Alliance News editor
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Glaxosmithkline (GSK)
